Completed PHASE3 INTERVENTIONAL 2-arm NCT05306704

High-Dose Vitamin D3 Supplementation in the Treatment of Human Immune Deficiency Virus Patients Trial (HDVDS-HIVT)

High-Dose Vitamin D3 Supplementation in the Treatment of Human Immune Deficiency Virus Patients: A Double-Blind Randomized Control Trial

Sponsor: The National HIV/AIDS Programme

Conditions HIV-1-infection Hypovitaminosis D

Interventions 25-Hydroxyvitamin D placebo Oil

Updated 3 times since 2022 Last updated: Apr 1, 2022 Started: Feb 15, 2019 Primary completion: Jan 31, 2022 Completion: Jan 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on HIV-1-infection and Hypovitaminosis D, this trial is completed. The trial is conducted by The National HIV/AIDS Programme and has accumulated 3 data snapshots since 2019. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
May 2022 — Jul 2024 [monthly]

Completed PHASE3

First recorded

Feb 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The National HIV/AIDS Programme
University of the Punjab

Data source: University of the Punjab

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lahore, Pakistan